ArticleFrontiers in pediatrics2026
Complement-related genetic analysis for Japanese children with transplant-associated thrombotic microangiopathy.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transplant-associated thrombotic microangiopathy (TA-TMA) is a life-threatening complication of hematopoietic stem cell transplantation (HSCT). Previous reports in the United States have suggested that TA-TMA is caused by complement-related genetic variants. However, these findings need to be validated in other countries and ethnic populations. Methods: We performed targeted sequencing of 40 complement-and coagulopathy-related genes in 44 Japanese pediatric patients who underwent HSCT, including 20 patients with TA-TMA and 24 patients without TA-TMA. Seventeen genes reported to be related to TA-TMA were included. Additionally, 23 genes that are thought to be associated with complement system activation and coagulopathy were investigated. Results: There was no significant difference in the percentage of patients bearing genetic variants between patients with and without TA-TMA. Furthermore, no marked differences in the percentage of patients or the average number of rare variants per patient were found between the two groups. Although we identified several rare non-synonymous variants in TA-TMA patients, we did not find any known pathogenic variants causing TA-TMA. Interestingly, a novel rare genetic variant in the Conclusion: In this limited number of Japanese pediatric cohort with TA-TMA, we could not find an enrichment of rare variants among 40 complement- and coagulopathy-related genes. A novel, rare variant of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.